
**A close-up of hands holding a tablet and a pen

Description automatically generatedAustria Diabetes Care Devices Market**

According to Intelli, the Austria diabetes care devices market was valued at USD 162.91 million in 2024 and is projected to reach USD 324.11 million by 2032, growing at a CAGR of 9.88% from 2024 to 2032.



Austria's diabetes care devices market is expanding steadily due to a rising prevalence of diabetes, particularly Type 2, increasing awareness of glucose monitoring, and strong healthcare infrastructure support. With the Austrian population aging and the incidence of obesity and sedentary lifestyles increasing, demand for continuous glucose monitors (CGMs), insulin pens, pumps, and self-monitoring blood glucose (SMBG) devices is growing.

Reimbursement policies, patient education initiatives, and the presence of advanced hospital systems further drive market growth. Technological advancements such as non-invasive glucose monitors, integration with smartphones, and closed-loop insulin delivery systems (artificial pancreas) are reshaping patient management.

**Austria Diabetes Care Devices Market Definition**

Diabetes care devices refer to electronic and mechanical tools used for monitoring and managing blood glucose levels and insulin administration. These include blood glucose meters, test strips, lancets, CGMs, insulin pumps, insulin pens, and smart diabetes management platforms. These devices aim to maintain glycemic control, reduce complications, and improve quality of life for patients with diabetes.

**Austria Diabetes Care Devices Market Overview**

The Austrian diabetes care market benefits from a universal healthcare system, early diagnosis programs, and access to modern treatment protocols. CGMs and insulin delivery systems are gaining wider acceptance due to patient convenience and accuracy. Austria’s national diabetes strategy, which focuses on prevention, early diagnosis, and digital health integration, supports the uptake of innovative devices.

A close-up of hands holding a tablet and a pen

Description automatically generatedHowever, challenges remain, such as high costs for newer technologies, variations in reimbursement coverage across states, and gaps in rural access. Nonetheless, Austria's focus on digital transformation, personalized care, and expanding telehealth services presents lucrative opportunities for manufacturers.

**Austria Diabetes Care Devices Market Segmentation Analysis Market Segmentation by Product** **Type:**

• Blood Glucose Monitoring Devices

• Self-Monitoring Blood Glucose (SMBG) Devices

• Continuous Glucose Monitoring (CGM) Devices

• Insulin Delivery Devices

• Insulin Pens

• Insulin Pumps

• Others

Blood glucose monitoring devices dominate the market, driven by increasing adoption of SMBG and CGMs for continuous data and better glycemic control. Insulin pens and pumps are seeing increased usage among young and active patients seeking discreet and accurate insulin administration.

**Market Segmentation by Distribution Channel:**

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

• Diabetes Clinics

A close-up of hands holding a tablet and a pen

Description automatically generatedHospital and retail pharmacies lead the segment due to their accessibility, while online channels are gaining popularity due to convenience and better price transparency. Diabetes clinics are important for device training and education.

**Market Segmentation by End User:**

• Hospitals

• Homecare Settings

• Diagnostic Centers

Homecare settings account for a significant share due to the preference for self-monitoring and ease of use. Hospitals still play a crucial role for newly diagnosed patients and complicated cases.

**Market Segmentation by Region:**

• Eastern Austria

• Western Austria

Eastern Austria, particularly Vienna, leads the market owing to higher population density, better healthcare infrastructure, and more specialist clinics. Western Austria, though smaller, is experiencing growth due to increasing awareness and access.

**Key Players**

The Austria diabetes care devices market features both global and regional players offering advanced and affordable solutions. Key players include Abbott Laboratories, Medtronic plc, F. Hoffmann-La Roche Ltd, Ascensia Diabetes Care, Dexcom Inc., Ypsomed Holding AG, Becton Dickinson and Company (BD), and Sanofi.

**Key Developments**

A close-up of hands holding a tablet and a pen

Description automatically generated• March 2024: Dexcom launched its G7 Continuous Glucose Monitoring System in Austria, providing real-time insights and compatibility with wearable tech.

• January 2024: Ypsomed expanded its partnership with CamDiab and Abbott to accelerate artificial pancreas rollouts in Austria.

Market Attractiveness Austria’s market is attractive due to its strong healthcare system, well-established reimbursement policies, and high awareness of diabetes management. Innovations in digital monitoring, combined therapy solutions, and the growing demand for homecare technologies enhance investment opportunities.

**Porter’s Five Forces**

• Threat of New Entrants: Moderate Technological requirements and compliance with EU MDR make entry challenging.

• Bargaining Power of Suppliers: Low. Numerous suppliers and standardized components reduce individual power.

• Bargaining Power of Buyers: High. Centralized procurement by healthcare institutions creates pricing pressure.

• Threat of Substitutes: Moderate. Lifestyle changes and oral medications are alternatives but cannot fully replace device-based care.

• Industry Rivalry: High. Multiple global players and continuous innovation keep competition strong.

**A close-up of hands holding a tablet and a pen

Description automatically generatedTABLE OF CONTENTS**

1. **INTRODUCTION OF AUSTRIA DIABETES CARE DEVICES MARKET**

1.1 Overview of the Market

1.2 Scope of Report

1.3 Assumptions

1. **EXECUTIVE SUMMARY**
2. **RESEARCH METHODOLOGY**

3.1 Data Mining

3.2 Validation

3.3 Primary Interviews

3.4 List of Data Sources

1. **AUSTRIA DIABETES CARE DEVICES MARKET OUTLOOK**

4.1 Overview

4.2 Market Dynamics

4.2.1 Drivers

4.2.2 Restraints

4.2.3 Opportunities

4.2.4 Trends

4.3 Porters Five Force Model

A close-up of hands holding a tablet and a pen

Description automatically generated4.4 Value Chain Analysis

1. **AUSTRIA DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE**

5.1 Blood Glucose Monitoring Devices

5.2 Self-Monitoring Blood Glucose (SMBG) Devices

5.3 Continuous Glucose Monitoring (CGM) Devices

5.4 Insulin Delivery Devices

5.5 Insulin Pens

5.6 Insulin Pumps

5.7 Others

1. **AUSTRIA DIABETES CARE DEVICES MARKET, BY DISTRIBUTION CHANNEL**

6.1 Hospital Pharmacies

6.2 Retail Pharmacies

6.3 Online Pharmacies

6.4 Diabetes Clinics

1. **AUSTRIA DIABETES CARE DEVICES MARKET, BY END USER**

7.1 Hospitals

7.2 Homecare Settings

7.3 Diagnostic Centers

1. **A close-up of hands holding a tablet and a pen

   Description automatically generatedAUSTRIA DIABETES CARE DEVICES MARKET, BY REGION**

8.1 Eastern Austria

8.2 Western Austria

1. **AUSTRIA DIABETES CARE DEVICES MARKET COMPETITIVE LANDSCAPE**

9.1 Overview

9.2 Company Market Ranking

9.3 Key Development Strategies

1. **COMPANY PROFILES**

**10.1 Abbott Laboratories**  
10.1.1 Overview   
10.1.2 Financial Performance   
10.1.3 Product Outlook   
10.1.4 Key Developments

**10.2 Medtronic plc**  
10.2.1 Overview   
10.2.2 Financial Performance   
10.2.3 Product Outlook   
10.2.4 Key Developments

**10.3 F. Hoffmann-La Roche Ltd**  
10.3.1 Overview   
10.3.2 Financial Performance   
10.3.3 Product Outlook   
10.3.4 Key Developments

**10.4 Ascensia Diabetes Care**  
10.4.1 Overview   
10.4.2 Financial Performance   
10.4.3 Product Outlook   
10.4.4 Key Developments

**A close-up of hands holding a tablet and a pen

Description automatically generated10.5 Dexcom Inc.**  
10.5.1 Overview   
10.5.2 Financial Performance   
10.5.3 Product Outlook   
10.5.4 Key Developments

**10.6 Ypsomed Holding AG**  
10.6.1 Overview   
10.6.2 Financial Performance   
10.6.3 Product Outlook   
10.6.4 Key Developments

**10.7 Becton Dickinson and Company (BD)**  
10.7.1 Overview   
10.7.2 Financial Performance   
10.7.3 Product Outlook   
10.7.4 Key Developments

**10.8 Sanofi**  
10.8.1 Overview   
10.8.2 Financial Performance   
10.8.3 Product Outlook   
10.8.4 Key Developments

1. **KEY DEVELOPMENTS**

11.1 Product Launches/Developments

11.2 Mergers and Acquisitions

11.3 Business Expansions

A close-up of hands holding a tablet and a pen

Description automatically generated11.4 Partnerships and Collaborations

1. **APPENDIX**

12.1 Related Research